AZ to acquire CinCor Pharma


United Kingdom

AstraZeneca Plc is taking steps to strengthen its position in therapies for cardiovascular and and kidney diseases with the acquisition of CinCor Pharma Inc, a US based company whose lead product, baxdrostat, is in clinical development for blood pressure lowering. The transaction is expected to create new opportunities for treating uncontrolled hypertension as well as chronic kidney disease. In particular, baxdrostat could be combined with Farxiga, an approved medicine for diabetes, heart failure and kidney disease, AstraZeneca said on 9 January.